基石藥業-B(02616.HK)PD-L1x4-1BBxHSA多特異性抗體CS2006/NM21-1480中國臨試申請獲NMPA受理,管線2.0戰略進一步深化與拓展
格隆匯7月7日丨基石藥業-B(02616.HK)發佈公吿,靶向PD-L1、4-1BB、和人血清蛋白("HSA)的多特異性抗體CS2006/NM21-1480在中國的新藥臨牀試驗申請("IND)獲中國國家藥品監督管理局("NMPA)藥品審評中心受理。這標誌着基石藥業管線2.0戰略進一步深化和拓展。基石藥業前瞻性地打造了創新管線2.0戰略,聚焦於新興療法中的全球同類首創、同類最優產品,並擁有更多的全球權益。
CS2006/NM21-1480是一種針對PD-L1、4-1BB和HSA的單價三特異性抗體片斷分子,其獨特的分子設計和創新的作用機制賦予其多種有利的特性,可以降低毒性並提高療效。作為一種潛在的同類最佳藥物,CS2006/NM21-1480是一種新的腫瘤免疫療法,可能與多種療法聯合使用。
基石藥業首席科學官謝毅釗博士表示:"此次CS2006/NM21-1480的IND獲受理是基石藥業管線2.0戰略進程中的一個重要里程碑。該產品已於2020年4月在美國獲批進入早期臨牀開發階段,目前該研究在積極進行中。未來,我們將快速推進包括CS2006/NM21-1480在內的多個創新藥物的研發,儘早為廣大的癌症患者提供優質的創新療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.